Levonorgestrel-Releasing Intrauterine Device is an Efficacious Contraceptive for Women with Leiomyoma

Women's Hospital, College of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.
The Journal of international medical research (Impact Factor: 1.44). 10/2012; 40(5):1966-72. DOI: 10.1177/030006051204000538
Source: PubMed


To evaluate the efficacy of a levonorgestrel-releasing intrauterine device (LNG-IUD) as contraception for women with uterine leiomyoma.
Thirty women with uterine leiomyoma requiring contraception were enrolled and had a LNG-IUD inserted. Menstrual blood volume (assessed by a pictorial blood loss assessment chart [PBAC]), haemoglobin concentration, volume of uterus and leiomyoma were determined before and after LNG-IUD insertion.
The median (range) PBAC score was 145.0 (60.0 - 232.0) before LNG-IUD insertion, which significantly decreased to 44.0 (0.0 - 99.0) and 36.0 (0.0 - 90.0) after 6 and 12 months of LNG-IUD use, respectively. Prior to LNG-IUD insertion, the median haemoglobin concentration in patients with anaemia was 100.0 (69.0 - 109.0) g/l and this increased significantly after 6 and 12 months of LNG-IUD use, to 117.5 (101.0 - 131.0) g/l and 119.5 (108.0 - 135.0) g/l, respectively. There were no significant changes in uterine or leiomyoma volumes. No patient became pregnant and there were no severe side-effects; one IUD was expulsed.
The LNG-IUD may be a safe and effective contraceptive for women of reproductive age with uterine leiomyoma.

1 Follower
16 Reads


16 Reads
Available from